CRO inVentiv Health and biotech partner Oncobiologics have a plot to cash in on the burgeoning market for knockoffs of biotech drugs, and the two have begun development on a biosimilar of the blockbuster Humira.
Parexel International has approved a stock repurchase program of up to $150 million, and the company plans to use its existing cash and credit to buy up its own shares and boost investor value.
Four pharma service providers, led by MPI Research, have joined forces to form KPI Therapeutics, a new biotech designed to develop promising drug candidates and speed their way to market.
Lincoln, NE, CRO Celerion has opened up shop in Singapore, following through on its efforts to tap the fast-growing Asian market for clinical research.
Clinical trial software provider TrialScope has acquired most of Deloitte's life sciences analytics business, picking up a $5 million investment as it works to expand its share of the eClinical market.
Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.
As many drugmakers scale down their R&D presences in India, Bristol-Myers Squibb is strengthening its relationship with Syngene, the CRO arm of local giant Biocon.
CRO Parexel International has been working to better unify its disparate service divisions, and now the company has named its first chief scientific officer to oversee its end-to-end offerings.
In the midst of an ongoing reorganization, contract developer AMRI has made another buy in manufacturing, signing a deal to scoop up CMO OsoBio for $110 million in cash.
WuXi PharmaTech has increased its manufacturing capabilities in China, bolstering its fastest-growing business as it looks to expand around the globe.
Global CRO INC Research has teamed up with a trade group of clinical research sites, lending its expertise in an effort to better integrate sponsors, CROs and investigators in the R&D process.
German researcher Evotec has signed a deal to pay as much as $5.3 million for specialty CRO Euprotec, a company focused on anti-infective drug discovery.
Vaccine developer Advaxis is teaming up with CRO inVentiv Health to advance a stable of oncology candidates that work by mounting an immune system attack on cancer tissue.
Clinical trial software provider Clinverse has inked a deal with eClinical Insights to share resources and unite their technologies.
U.K. outsourcers PolyTherics and Antitope have merged to pool their R&D resources, christening the combined company Abzena and targeting the bustling biomedical hub of Cambridge for new headquarters.
Rho, a midsize contract researcher out of North Carolina, is looking to expand its footprint to deal with a widening client base, setting out to expand its ranks of investigators and execs.
Cloud-based data magnate Medidata has signed a deal with TransCelerate BioPharma, a consortium of the world's largest drugmakers, to modernize the way the industry conducts clinical trials.
As the industry embraces risk-based clinical trial monitoring, Parexel International is expanding its banner eClinical offering to help sponsors make data-driven decisions in the middle of a study.
Global CRO Covance is looking to expand its share of the drug-commercialization space, buying up a U.K. market access specialist to help its clients sell their approved products.
China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.